ProQR Therap (PRQR)
ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops a...
- Open
- 1.930
- High
- 2.160
- Low
- 1.890
- Prev. Close
- 1.930
- Volume
- 1.56M
- Turnover
- 3.17M
- Avg Price
- 2.035
- Bid/Ask Ratio
- --
- Amplitude
- 13.99%
- 52wk High
- 3.100
- Volume Ratio
- 1.24
- Turnover Ratio
- 1.70%
ProQR Therap Analyst Rating
View moreForecast & Rating
Aug 17, 2026Price forecast
$8.25283.72%
Forecast & RatingStrong buy
8analysts
- Strong buy87.50%
- Buy12.50%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · Aug 13 at 06:03 AM
ProQR Q2 FY26 net loss narrows to EUR 8.7 million
- PUBT · Aug 3 at 03:01 PM
ProQR CEO Daniel Anton de Boer acquires 200,000 shares for $353,960
- Market Beat · Jul 30 at 06:26 AM
ProQR Therapeutics (PRQR) to Announce Earnings on Thursday
- Global Report · Jul 22 at 04:17 AM
Gene Editing's 2026 Reality Check: Billion-Dollar Bets and the AI Horizon
- Tip Ranks · Jul 21 at 09:00 PM
ProQR Director Makes Bold Insider Move With New Share Purchase
- PUBT · Jul 21 at 07:00 AM
ProQR Therapeutics director Bart Filius buys $257,925 of common shares
